BETTER, AFFORDABLE THERAPEUTICS THAT IMPROVE THE LIFE OF PATIENTS

AltruBio is a clinical-stage pharmaceutical company focused on developing novel antibody therapeutics for the treatment of immunological diseases with high unmet medical needs. Based on unique insights into immune tolerance and epitope dominance sciences, AltruBio’s pipeline focuses on depleting unwanted activated T cells with proof of mechanism in four autoimmune and inflammatory diseases. The Company’s pipeline includes programs aimed at combatting acute Graft Versus Host Disease, Psoriatic Arthritis and Ulcerative Colitis.